What Is KLOW 80mg? GHK-Cu, BPC-157, TB-500 and KPV Blend Explained

KLOW 80mg is a four-component research blend represented as GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg, for a total nominal content of 80mg. Unlike a single peptide, KLOW does not have one amino-acid sequence, one molecular formula or one single-compound analytical identity. It is a mixture of chemically distinct peptide materials.

That distinction determines how the scientific evidence and analytical documentation should be interpreted. Published research exists for the individual components, but a literature search does not establish a controlled clinical evidence base for the exact four-component KLOW formulation itself.

KLOW 80mg Composition

  • GHK-Cu: 50mg nominal content
  • BPC-157: 10mg nominal content
  • TB-500: 10mg nominal content
  • KPV: 10mg nominal content
  • Total nominal content: 80mg

The blend name is therefore a convenient formulation label rather than the name of one molecule.

Why KLOW Should Be Treated as a Mixture, Not a Single Peptide

Each component has its own molecular structure, expected mass, chromatographic behaviour and scientific literature. When the four materials are combined, those individual identities do not disappear.

This has several consequences:

  • one molecular formula cannot describe the whole blend;
  • one molecular mass cannot identify the whole blend;
  • component-level evidence does not automatically establish blend-level effects;
  • analytical methods need to account for multiple intended analytes; and
  • a batch COA should identify the formulation clearly enough to distinguish the four components.

Component 1: GHK-Cu 50mg

GHK is the naturally occurring tripeptide glycyl-L-histidyl-L-lysine. It can form a complex with copper(II), producing GHK-Cu. GHK has been identified in human biological fluids, and a substantial body of preclinical and cosmetic-biochemistry literature has investigated copper binding, extracellular-matrix biology, fibroblast signalling and tissue-repair-associated pathways.

Reviews describe effects on collagen and glycosaminoglycan regulation, metalloproteinase systems and cell-signalling pathways. However, the evidence varies by experimental model and should not be converted into broad therapeutic claims.

For the existing Australian Peptide literature review, see Understanding GHK-Cu in Modern Biochemistry Literature.

Component 2: BPC-157 10mg

BPC-157 is a synthetic 15-amino-acid peptide that has been studied predominantly in preclinical models. Published experimental work includes tendon-fibroblast migration, angiogenesis-associated pathways and multiple injury models.

A 2026 review is particularly important for evidence quality. It concluded that despite decades of preclinical research, BPC-157 remains pharmaceutically underdeveloped, with no approved formulation, no validated dosing regimen and no completed Phase II clinical trial. That evidence boundary should be stated clearly whenever BPC-157 is discussed.

See Understanding BPC-157 in Modern Biochemistry Literature.

Component 3: TB-500 10mg — An Important Identity Nuance

TB-500 requires unusually careful nomenclature. It is often described online as if it were simply another name for full-length thymosin beta-4. Analytical literature demonstrates why that is not always reliable.

A 2012 HPLC/high-resolution-mass-spectrometry study examined a product identified as TB-500 and detected the N-terminally acetylated thymosin beta-4 17-23 fragment, Ac-LKKTETQ. This means researchers should not automatically assume that every material called TB-500 is the intact 43-residue thymosin beta-4 molecule.

Research on full-length thymosin beta-4 can provide biological context, including actin-binding and cell-migration research, but those findings should not automatically be transferred to a shorter TB-500 fragment unless the molecular identity has been confirmed.

See Understanding TB-500 in Modern Biochemistry Literature.

Component 4: KPV 10mg

KPV is the tripeptide Lys-Pro-Val, corresponding to the C-terminal three residues of alpha-MSH. Experimental research has investigated KPV in inflammatory-signalling systems, including studies involving NF-kappaB pathways and PepT1-mediated tripeptide transport.

Published work suggests that KPV’s reported activity is not readily explained by classical melanocortin-receptor binding, despite its origin within the alpha-MSH sequence. Most evidence is mechanistic, cellular or animal-based rather than a mature human clinical evidence base.

For the dedicated guide, see What Is KPV?.

Has the Exact KLOW Blend Been Clinically Studied?

There is no strong controlled clinical evidence base establishing the exact 50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500 + 10mg KPV combination as one clinically validated formulation.

This is an important distinction because a blend can accumulate a large amount of component-level literature without the blend itself ever being tested as a fixed formulation. Scientific articles should therefore describe KLOW as a co-formulated research mixture and clearly identify which findings come from which constituent.

Why Multi-Peptide HPLC Is More Difficult

A single-peptide HPLC chromatogram starts with one intended principal analyte. A KLOW chromatogram starts with at least four intended components, and the components differ substantially in size, polarity and chemistry.

GHK-Cu is a copper-associated tripeptide complex, KPV is a very small tripeptide, BPC-157 is a 15-residue peptide, and TB-500 identity itself requires exact molecular definition. A single reverse-phase method may not resolve all components optimally.

Questions that matter include:

  • Are all four intended components retained and detected under the method?
  • Are any components co-eluting?
  • Does the detector respond comparably to each peptide?
  • Is “purity” being reported for each component or as an overall chromatographic statistic?
  • Does the method distinguish free GHK from the copper-associated form?

For the fundamentals, see Understanding HPLC Purity.

LC-MS and Component Identification

Mass spectrometry can help identify multiple intended molecular species after chromatographic separation. For KLOW, the analytical question is not “Does the blend have the correct mass?” because there is no single correct mass for the mixture. Instead, the question becomes whether analytical evidence supports the identity of each specified constituent.

This is especially important for TB-500, where marketplace naming can conceal differences between full-length thymosin beta-4 and shorter fragments.

Purity Is Not the Same as Quantity

Another common analytical error is treating a high purity percentage as proof that a vial contains the labelled milligram amount. Those are different measurements.

Purity describes the relative composition of detected material under the analytical method. Content or quantity asks how much of a specified analyte is actually present. An 80mg blend claim requires meaningful component-level quantity information if exact composition is important to the research.

Certificate of Analysis Requirements for KLOW

A strong KLOW batch record should state the complete formulation and link it to the production batch. Ideally, documentation should address:

  • GHK-Cu identity and nominal content;
  • BPC-157 identity and nominal content;
  • the exact molecular identity intended by “TB-500”;
  • KPV identity and nominal content;
  • the total nominal 80mg formulation;
  • analytical methods used; and
  • the batch identifier matching the physical vial.

A COA for one constituent is not a COA for the four-component blend. See Certificate of Analysis Explained and the COA Library.

KLOW Compared With GLOW

Australian Peptide’s existing GLOW research article describes a three-component mixture of GHK-Cu, BPC-157 and TB-500. KLOW adds a fourth component, KPV. That changes both the formulation and the analytical problem.

Researchers should not assume that a GLOW batch report verifies KLOW or that adding KPV leaves the analytical profile unchanged. Each formulation needs its own batch-specific documentation.

See What Is the GLOW Research Peptide Blend?.

Frequently Asked Questions

What does KLOW 80mg contain?

The stated formulation is GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg, totalling 80mg.

Is KLOW one peptide?

No. It is a four-component peptide blend.

Does KLOW have one molecular weight?

No. Each component has its own molecular identity and expected mass.

Has the exact KLOW formulation been validated in controlled human trials?

A robust controlled clinical evidence base for the exact four-component KLOW formulation has not been established. Most relevant published evidence concerns individual components.

Is TB-500 always full-length thymosin beta-4?

No assumption should be made. Published analytical work identified an acetylated thymosin beta-4 17-23 fragment in a product sold as TB-500, so exact molecular identity should be verified.

Can one purity percentage prove 50mg + 10mg + 10mg + 10mg?

No. Purity and quantitative content are different analytical questions.

Selected Scientific References

Related Research Resources

This article is provided for laboratory, analytical and scientific education only. It does not provide dosing, administration, injection, therapeutic or personal-use guidance.

Back to blog